{"id":"NCT04542070","sponsor":"ViiV Healthcare","briefTitle":"A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVYÂ® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed","officialTitle":"A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-09","primaryCompletion":"2022-07-13","completion":"2023-04-17","firstPosted":"2020-09-09","resultsPosted":"2023-09-13","lastUpdate":"2024-06-04"},"enrollment":687,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections"],"interventions":[{"type":"DRUG","name":"Cabotegravir Tablets","otherNames":[]},{"type":"DRUG","name":"Cabotegravir Injectable Suspension (CAB LA)","otherNames":[]},{"type":"DRUG","name":"Rilpivirine Tablets","otherNames":[]},{"type":"DRUG","name":"Rilpivirine Injectable Suspension (RPV LA)","otherNames":[]},{"type":"DRUG","name":"BIKTARVY Tablets (BIK)","otherNames":[]}],"arms":[{"label":"Biktarvy (BIK)","type":"ACTIVE_COMPARATOR"},{"label":"Oral lead-in phase (OLI)","type":"EXPERIMENTAL"},{"label":"Direct to injections (D2I)","type":"EXPERIMENTAL"},{"label":"Switch Q2M Group","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.","primaryOutcome":{"measure":"Percentage of Participants With Plasma Human Immunodeficiency Viruses (HIV)-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=) 50 Copies Per Milliliter (c/mL) at Month 12/11 - ITT-E Population","timeFrame":"At month 12/11","effectByArm":[{"arm":"Q2M (OLI + D2I)","deltaMin":1.3,"sd":null},{"arm":"Biktarvy (BIK)","deltaMin":0.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":37},"locations":{"siteCount":117,"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Ireland","Italy","Japan","Netherlands","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["36626155","37567205","40383512","39676239"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":175},"commonTop":["Injection site pain","COVID-19","Headache","Pyrexia","Injection site nodule"]}}